Pascale Boissel appointed new member of Innate’s Supervisory Board
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announces the results of the vote of its shareholders at the Annual General Meeting (“AGM”) which took place on May 19, 2020, in Marseille, France without the physical presence of its shareholders. All resolutions were voted in accordance with the Executive Board’s recommendations.
A total of 43,629,034 votes were cast out of a total of 79,698,670 shares with voting rights, representing a quorum of 55.300%.
These resolutions, the results of the votes and other documents relating to the AGM are available in the Annual General Meeting 2020 section of the Company’s website: https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting.
The 2019 20-F of the Company is available on its website.
During the meeting, Pascale Boissel was appointed as a new member of the Supervisory Board and member of the Audit Committee.
With more than 30 years of financial experience, Mrs. Boissel is an expert in finance, audit, transactions, internal control, growth management and restructuring operations. Her experience has been represented in a variety of industries, including: food and beverage (Danone), building materials (Lafarge Holcim), education, and health and biotechnology. She began her career in audit and corporate finance at PricewaterhouseCoopers Paris. Mrs. Boissel is currently a financial consultant and part-time CFO of Novadiscovery.